EyeBio

Executive Summary

EyeBio is a private, clinical-stage biotechnology company headquartered in New York, focused on developing novel therapeutics for serious retinal diseases such as geographic atrophy and diabetic macular edema. Founded in 2021, the company has raised $65M and is advancing its lead candidate through Phase 2 trials, leveraging biologics and small molecules to address high unmet needs in ophthalmology. Early clinical data has been promising, positioning EyeBio as a potential player in the retinal disease space. The company's near-term focus is on progressing its lead asset through key clinical milestones. With a strong scientific foundation and a clear unmet need in retinal disease, EyeBio is poised for potential value inflection from upcoming data readouts. The company may also seek additional financing or partnership opportunities to extend its runway and support further pipeline development. Investors should monitor for Phase 2 results and strategic announcements that could unlock significant upside.

Upcoming Catalysts (preview)

• Q4 2026Phase 2 Data Readout for Lead Candidate70% success
• H2 2026Series C Financing Round65% success
• Q3 2026FDA Orphan Drug Designation for Lead Candidate75% success